Core Viewpoint - The company has successfully completed the enrollment of 195 patients in a real-world study for its product OT-703 (ILUVIEN®), which is used to treat diabetic macular edema (DME) [1] Group 1: Product Information - OT-703 is an injectable, non-biodegradable fluocinolone acetonide intravitreal implant that provides continuous release of a small amount of non-proprietary corticosteroid for up to 36 months to treat DME [2] - It is the only FDA-approved intravitreal implant that offers a sustained release for up to 3 years for the treatment of DME [2] - The product has received regulatory approval from the FDA and is marketed under the brand name "ILUVIEN®" [2] Group 2: Licensing and Approvals - In April 2021, the company entered into an exclusive licensing agreement with Alimera Sciences, Inc., granting it exclusive rights for the development and commercialization of ILUVIEN® in Greater China, South Korea, and 11 Southeast Asian countries [2] - In December 2023, OT-703 received approval from the Hong Kong Pharmacy and Poisons Board to be registered as a pharmaceutical product under the Pharmacy and Poisons Ordinance [2]
欧康维视生物-B(01477.HK)：OT-703于海南博鳌进行的真实世界研究完成患者入组